Ceftriaxone crystallization and its potential role in kidney stone formation

Biochemical and Biophysical Research Communications

Volumn 406, Issue 3, 2011, Pages 396-402

  Chutipongtanate, Somchai ^a   Thongboonkerd, Visith ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Ceftriaxone; Crystal adhesion; Crystallization; Kidney stone; Nephrolithiasis

Indexed keywords

CALCIUM CHLORIDE; CEFTRIAXONE;

ANIMAL CELL; ARTICLE; CALCIUM DEPLETION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; KIDNEY CONCENTRATING CAPACITY; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; STONE FORMATION; URINARY EXCRETION; URINE;

ANIMALS; ANTI-BACTERIAL AGENTS; CALCIUM; CEFTRIAXONE; CELL ADHESION; CELL LINE; CRYSTALLIZATION; DOGS; HUMANS; KIDNEY CALCULI; NEPHROLITHIASIS;

EID: 79952738342     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.053     Document Type: Article

References (26)

1. Coe F.L., Evan A., Worcester E. Kidney stone disease. J. Clin. Invest. 2005, 115:2598-2608.
2. Daudon M., Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 2004, 64:245-275.
3. Pak C.Y., Sakhaee K., Hwang T.I., Preminger G.M., Harvey J.A. Nephrolithiasis from calcium supplementation. J. Urol. 1987, 137:1212-1213.
4. Noe H.N., Bryant J.F., Roy S., Stapleton F.B. Urolithiasis in pre-term neonates associated with furosemide therapy. J. Urol. 1984, 132:93-94.
5. Ahlstrand C., Tiselius H.G. Urine composition and stone formation during treatment with acetazolamide. Scand. J. Urol. Nephrol. 1987, 21:225-228.
6. Dick W.H., Lingeman J.E., Preminger G.M., Smith L.H., Wilson D.M., Shirrell W.L. Laxative abuse as a cause for ammonium urate renal calculi. J. Urol. 1990, 143:244-247.
7. McLain D.A., Garriga F.J., Kantor O.S. Adverse reactions associated with ticrynafen use. JAMA 1980, 243:763-764.
8. Grunberg R.W., Silberg S.J. Triamterene-induced nephrolithiasis. JAMA 1981, 245:2494-2495.
9. Farina L.A., Palou R.J., Chechile T.G. Reversible acute renal failure due to sulfonamide-induced lithiasis in an AIDS patient. Arch. Esp. Urol. 1995, 48:418-419.
10. Daudon M., Estepa L., Viard J.P., Joly D., Jungers P. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997, 349:1294-1295.
11. Farrer J.H., Rajfer J. Silicate urolithiasis. J. Urol. 1984, 132:739-740.
12. Feher G., Benczik A., Szabo E., Rethy I., Berenyi M. Renal gravel formation inducing renal insufficiency as a side-effect of ceftriaxon. Orv. Hetil. 1999, 140:769-771.
13. Avci Z., Koktener A., Uras N., Catal F., Karadag A., Tekin O., Degirmencioglu H., Baskin E. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch. Dis. Child. 2004, 89:1069-1072.
14. Mohkam M., Karimi A., Gharib A., Daneshmand H., Khatami A., Ghojevand N., Sharifian M. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr. Nephrol. 2007, 22:690-694.
15. Steadman E., Raisch D.W., Bennett C.L., Esterly J.S., Becker T., Postelnick M., McKoy J.M., Trifilio S., Yarnold P.R., Scheetz M.H. Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob. Agents Chemother. 2010, 54:1534-1540.
16. Stojanovic V., Djuric V.G. Nephrolithiasis caused by ceftriaxone in a 3-year-old child with ureteropelvic junction obstruction. Case Rep. Med. 2009, 2009:365962.
17. de Moor R.A., Egberts A.C., Schroder C.H. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur. J. Pediatr. 1999, 158:975-977.
18. Tasic V., Sofijanova A., Avramoski V. Nephrolithiasis in a child with acute pyelonephritis. Ceftriaxone-induced nephrolithiasis and biliary pseudolithiasis. Pediatr. Nephrol. 2005, 20:1510-1513.
19. Patel I.H., Chen S., Parsonnet M., Hackman M.R., Brooks M.A., Konikoff J., Kaplan S.A. Pharmacokinetics of ceftriaxone in humans. Antimicrob. Agents Chemother. 1981, 20:634-641.
20. Chutipongtanate S., Thongboonkerd V. Systematic comparisons of artificial urine formulas for in vitro cellular study. Anal. Biochem. 2010, 402:110-112.
21. Chutipongtanate S., Thongboonkerd V. Establishment of a novel colorimetric assay for high-throughput analysis of calcium oxalate crystal growth modulation. Analyst 2010, 135:1309-1314.
22. Saier M.H. Growth and differentiated properties of a kidney epithelial cell line (MDCK). Am. J. Physiol. 1981, 240:C106-C109.
23. Lieske J.C., Deganello S. Nucleation, adhesion, and internalization of calcium-containing urinary crystals by renal cells. J. Am. Soc. Nephrol. 1999, 10(Suppl 14):S422-S429.
24. Ryall R.L. Glycosaminoglycans, proteins, and stone formation: adult themes and child's play. Pediatr. Nephrol. 1996, 10:656-666.
25. Thongboonkerd V., Chutipongtanate S., Semangoen T., Malasit P. Urinary trefoil factor 1 is a novel potent inhibitor of calcium oxalate crystal growth and aggregation. J. Urol. 2008, 179:1615-1619.
26. Rabinovich Y.I., Esayanur M., Daosukho S., Byer K.J., El Shall H.E., Khan S.R. Adhesion force between calcium oxalate monohydrate crystal and kidney epithelial cells and possible relevance for kidney stone formation. J. Colloid Interf. Sci. 2006, 300:131-140.